By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.

University of Iowa researchers have been awarded federal funding to help develop an effective drug combination to treat a ...

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups, according to a new study. The ...

Researchers at the University of Iowa are part of a project designed to enhance treatment options for a common form of liver ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

HCC risk prediction may be poorly reported and biased for individuals with nonviral chronic liver disease.